MYL : Summary for Mylan N.V. - Yahoo Finance

U.S. Markets closed

Mylan N.V. (MYL)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
40.35-1.37 (-3.28%)
At close: 4:00PM EDT

40.34 -0.01 (-0.02%)
After hours: 6:50PM EDT

People also watch
TEVAPRGOAGNBIIBENDP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close41.72
Open41.50
Bid40.26 x 200
Ask40.35 x 1000
Day's Range40.13 - 41.89
52 Week Range33.60 - 50.40
Volume10,250,610
Avg. Volume5,816,536
Market Cap21.61B
Beta1.45
PE Ratio (TTM)43.86
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Mylan Completes Acquisition of Cold-EEZE® Brand
    PR Newswire7 hours ago

    Mylan Completes Acquisition of Cold-EEZE® Brand

    HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the successful acquisition of the global rights to the Cold-EEZE® brand cold remedy line from ProPhase Labs, Inc. The transaction provides Mylan all assets and rights relating to the Cold-EEZE® brand, including all U.S. businesses and U.S. and international trademarks. The Cold-EEZE® family of brands includes leading over-the-counter (OTC) cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts® and oral liquid dose forms in the U.S.

  • Investopedia8 hours ago

    S&P edges up as energy gains, Vertex soars

    The benchmark S&P 500 edged up on Wednesday as the stronger energy sector and soaring shares of Vertex Pharmaceuticals offset declines in financial shares and investors began looking ahead to first-quarter ...

  • TheStreet.com9 hours ago

    FDA Rejection of Mylan Generic Adds to its Woes

    The company's shares were falling again on Wednesday, this time on the news that its initial application for an anti-asthma generic had been rejected by the FDA.